Hypermutation induced by APOBEC-1 overexpression can be eliminated

Area of Science:

• Molecular Biology
• Gene Therapy
• Biochemistry

Background:

• APOBEC-1 overexpression reduces apoB-100 but causes harmful hypermutation and potential liver tumors.
• The auxiliary factor ACF exacerbates APOBEC-1's nonspecific hypermutation and editing activity.

Purpose of the Study:

• To investigate methods to eliminate APOBEC-1's nonspecific hypermutation while retaining its therapeutic editing.
• To assess the potential of modified APOBEC-1 for safe gene therapy for hyperlipidemia.

Main Methods:

• Overexpression of APOBEC-1 and ACF in HepG2 cells and rat liver primary cultures.
• Site-specific mutations (P29F, E181Q) introduced into APOBEC-1.
• Analysis of apoB and NAT1 mRNA editing and APOBEC-1/ACF interaction.

Main Results:

• APOBEC-1/ACF overexpression caused significant hypermutation on apoB mRNA at multiple sites.
• APOBEC-1 mutants P29F and E181Q drastically reduced hypermutation on apoB and NAT1 mRNAs.
• Mutants retained significant specific editing activity and showed reduced APOBEC-1/ACF interaction.

Conclusions:

• Site-specific mutations in APOBEC-1 can eliminate nonspecific hypermutation without compromising therapeutic editing.
• Modified APOBEC-1 holds potential for safe and effective gene therapy for hyperlipidemia.
• Reduced APOBEC-1/ACF interaction is key to eliminating hypermutation.